Recombinant Synaptophysin (SYP) Homo sapiens (Human) Recombinant protein

Major synaptic vesicle protein p38

Add to Cart Distributors
Overview
Properties
  • Source Prokaryotic expression, Host E.coli
  • Endotoxin Level<1.0EU per 1µg (determined by the LAL method)
  • Subcellular LocationMembrane
  • Molecular Mass 10.1kDa, Accurate 13kDa(Analysis of differences refer to the manual)
  • Residues & TagsGlu50~Phe106 with N-terminal His Tag
  • Buffer FormulationPBS, pH7.4, containing 0.01% SKL, 5% Trehalose.
  • Traits Freeze-dried powder, Purity > 95%
  • Isoelectric Point4.1
Share your citation Upload your experimental result Review Leave a message
Loading...

Share a new citation as an author

Upload your experimental result

Review

Please attach serial No. on instruction manual

Contact us

Please fill in the blank.

Name*
Organization
Address
E-mail address*
Telephone
Inquiry*
Verification code* CheckCode
  • Recombinant Synaptophysin (SYP) Packages (Simulation)
  • Recombinant Synaptophysin (SYP) Packages (Simulation)
  • Recombinant Synaptophysin (SYP) Figure . Gene Sequencing (extract)
  • RPA425Hu01.jpg Figure. SDS-PAGE
  • Certificate ISO9001: 2008, ISO13485: 2003 Registered

Sequence

Usage

Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.

Storage

Avoid repeated freeze/thaw cycles. Store at 2-8°C for one month. Aliquot and store at -80°C for 12 months.

Stability

The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.

Citations

  • Increased Amyloid-β Peptide-Induced Memory Deficits in Phospholipid Transfer Protein (PLTP) Gene Knockout MiceNature: Source
  • BACLOFEN AND ACAMPROSATE BASED THERAPY OF NEUROLOGICAL DISORDERS Read more: http://www.faqs.org/patents/app/20130090307#ixzz3VGRXUqW9Faqs:Source
  • In Vivo Characterization of ARN14140, a Memantine/Galantamine-Based Multi-Target Compound for Alzheimer's Diseasepubmed:27609215
  • An Intranasal Formulation of Erythropoietin (Neuro-EPO) Prevents Memory Deficits and Amyloid Toxicity in the APPSwe Transgenic Mouse Model of Alzheimer's …articles:journal-of-alzheimers-disease
  • Investigating the roles of SRRM4 in contribution to neuroendocrine prostate cancer progression
  • Neuroprotection in non-transgenic and transgenic mouse models of Alzheimer's disease by positive modulation of σ1 receptorsPubmed: 31048034
  • Fermented Goat Milk Consumption Enhances Brain Molecular Functions during Iron Deficiency Anemia RecoveryPubmed: 31591353
  • Tunable Substrate Functionalities Direct Stem Cell Fate toward Electrophysiologically Distinguishable Neuron-like and Glial-like Cells33356098
  • Enriched Environment Minimizes Anxiety/Depressive-Like Behavior in Rats Exposed to Immobilization Stress and Augments Hippocampal Neurogenesis (In Vitro)33492617

Recommend products